THE SGLT2 INHIBITOR EMPAGLIFLOZIN CAUSES A GREATER REDUCTION IN SKIN SODIUM CONTENT AND INTERSTITIAL VOLUME THAN LOOP DIURETICS IN HEART FAILURE | Publicación